拓扑替康联合紫杉醇一线治疗晚期宫颈癌的最终生存分析:一项NRG肿瘤学随机研究
NRG肿瘤学GOG 240是一项3期随机开放标签试验,452例复发/转移性宫颈癌患者随机接受紫杉醇+拓扑替康(n=223)或顺铂+紫杉醇(n=229),每组再联合或不联合贝伐珠单抗。最终分析显示,顺铂-紫杉醇骨干的中位OS为16.3个月,拓扑替康-紫杉醇骨干为13.8个月(HR 1.12;95%CI 0.91-1.38;p=0.28);拓扑替康+紫杉醇未带来生存获益,不应常规推荐。
要点
- 最终分析中位OS:顺铂-紫杉醇骨干16.3个月 vs 拓扑替康-紫杉醇骨干13.8个月(HR 1.12;95%CI 0.91-1.38;p=0.28)。
- 既往铂暴露的75%患者中,中位OS顺铂-紫杉醇骨干14.6个月 vs 拓扑替康-紫杉醇骨干12.9个月(HR 1.09;95%CI 0.86-1.38;p=0.48)。
- 拓扑替康+紫杉醇不应在复发/转移性宫颈癌人群中常规推荐。
核心结论
- 拓扑替康联合紫杉醇未给复发/转移性宫颈癌女性带来生存获益,即使在铂暴露患者中也是如此;不应常规推荐拓扑替康-紫杉醇用于该人群。
研究设计与样本
- 妇科肿瘤组240方案是一项3期、随机、开放标签临床试验,共纳入452例复发/转移性宫颈癌患者,随机接受紫杉醇175 mg/m2+拓扑替康0.75 mg/m2第1-3天(n=223)或顺铂50 mg/m2+紫杉醇135或175 mg/m2(n=229);每种化疗双药方案联合或不联合贝伐珠单抗(15 mg/kg),每21天重复直至进展、不可接受的毒性或完全缓解;主要终点为OS和不良事件频率及严重程度,本报告为OS最终分析。
主要发现
- 方案指定的最终分析中,顺铂-紫杉醇骨干中位OS为16.3个月,拓扑替康-紫杉醇骨干为13.8个月(HR 1.12;95%CI 0.91-1.38;p=0.28)。
- 顺铂-紫杉醇与拓扑替康-紫杉醇的中位OS分别为15个月 vs 12个月(HR 1.10;95%CI 0.82-1.48;p=0.52)。
- 顺铂-紫杉醇-贝伐珠单抗与拓扑替康-紫杉醇-贝伐珠单抗的中位OS分别为17.5个月 vs 16.2个月(HR 1.16;95%CI 0.86-1.56;p=0.34)。
- 在研究人群中既往铂暴露的75%患者里,顺铂-紫杉醇骨干与拓扑替康-紫杉醇骨干的中位OS分别为14.6个月 vs 12.9个月(HR 1.09;95%CI 0.86-1.38;p=0.48)。
- 进展后生存:顺铂-紫杉醇骨干7.9个月 vs 拓扑替康-紫杉醇骨干8.1个月(HR 0.95;95%CI 0.75-1.19);两种化疗骨干间4级血液学毒性相似。
临床怎么用
- 作者认为拓扑替康-紫杉醇不应在复发/转移性宫颈癌人群中常规推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. METHODS: Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2 days 1-3 (n = 223) vs cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2 (n = 229), in 452 patients with recurrent/metastatic cervical cancer. Each chemotherapy doublet was also studied with and without bevacizumab (15 mg/kg). Cycles were repeated every 21 days until progression, unacceptable toxicity, or complete response. The primary endpoints were OS and the frequency and severity of adverse effects. We report the final analysis of OS. RESULTS: At the protocol-specified final analysis, median OS was 16.3 (cisplatin-paclitaxel backbone) and 13.8 months (topotecan-paclitaxel backbone) (HR 1.12; 95% CI, 0.91-1.38; p = 0.28). Median OS for cisplatin-paclitaxel and topotecan-paclitaxel was 15 vs 12 months, respectively (HR 1.10; 95% CI,0.82-1.48; p = 0.52), and for cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab was 17.5 vs 16.2 months, respectively (HR 1.16; 95% CI, 0.86-1.56; p = 0.34). Among the 75% of patients in the study population previously exposed to platinum, median OS was 14.6 (cisplatin-paclitaxel backbone) vs 12.9 months (topotecan-paclitaxel backbone), respectively (HR 1.09; 95% CI, 0.86-1.38;p = 0.48). Post-progression survival was 7.9 (cisplatin-paclitaxel backbone) vs 8.1 months (topotecan-paclitaxel backbone) (HR 0.95; 95% CI, 0.75-1.19). Grade 4 hematologic toxicity was similar between chemotherapy backbones. CONCLUSIONS: Topotecan plus paclitaxel does not confer a survival benefit to women with recurrent/metastatic cervical cancer, even among platinum-exposed patients. Topotecan-paclitaxel should not be routinely recommended in this population. NCT00803062.
引用
- Tewari KS, Sill MW, Birrer MJ, et al. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023. PMID: 36898292. doi:10.1016/j.ygyno.2023.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。